Pharma BD Deal Intelligence

Grünenthal GmbH / Bayer AG

2026 · Asset Purchase · $431M · Pending

Bayer agreed to sell global rights to its oncology product Stivarga (regorafenib) to the Gruenenthal Group for maximum consideration of EUR 375 million, approximately US$431 million. Stivarga is an oral multikinase inhibitor approved in more than 90 markets for metastatic colorectal cancer, gastrointestinal stromal tumors and hepatocellular carcinoma. Gruenenthal estimates Stivarga may contribute up to approximately EUR 100 million to consolidated EBITDA for the year ending 31 December 2027, assuming close by end of 2026 or early 2027 and full-year consolidation. Loss of exclusivity is anticipated in 2029 in the European Union and 2030 in the United States. The transaction is expected to complete by the end of 2026 or early 2027, subject to customary closing conditions.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals